CN106905320A - It is a kind of to be adapted to medicinal replace Buddhist nun and its preparation according to Shandong - Google Patents

It is a kind of to be adapted to medicinal replace Buddhist nun and its preparation according to Shandong Download PDF

Info

Publication number
CN106905320A
CN106905320A CN201510980745.3A CN201510980745A CN106905320A CN 106905320 A CN106905320 A CN 106905320A CN 201510980745 A CN201510980745 A CN 201510980745A CN 106905320 A CN106905320 A CN 106905320A
Authority
CN
China
Prior art keywords
buddhist nun
shandong
mixed solvent
acetone
medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510980745.3A
Other languages
Chinese (zh)
Inventor
郭家强
程睿
赵坤
徐维元
林祖鹏
蔡鸿飞
杨小玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HANGZHOU RONGLI MEDICINE SCIENCE & TECHNOLOGY Co Ltd
Original Assignee
HANGZHOU RONGLI MEDICINE SCIENCE & TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HANGZHOU RONGLI MEDICINE SCIENCE & TECHNOLOGY Co Ltd filed Critical HANGZHOU RONGLI MEDICINE SCIENCE & TECHNOLOGY Co Ltd
Priority to CN201510980745.3A priority Critical patent/CN106905320A/en
Publication of CN106905320A publication Critical patent/CN106905320A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Abstract

The present invention provides and a kind of is adapted to medicinal replace Buddhist nun and its preparation according to Shandong.It is described low for Buddhist nun's impurity content according to Shandong, thus drug safety is higher.Of the invention to replace Buddhist nun's preparation process is simple according to Shandong, with low cost, optimization and exploitation to medicine have important value.

Description

It is a kind of to be adapted to medicinal replace Buddhist nun and its preparation according to Shandong
Technical field
It is more particularly to a kind of to be adapted to medicinal replace Buddhist nun and its preparation according to Shandong the present invention relates to chemical medicine.
Background technology
B cell malignant tumour includes chronic lymphocytic leukemia (CLL), ALL (ALL), small pouring Bar cell lymphoma (SLL), lymphoma mantle cell (MCL), follicular lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), Huppert's disease (MM) andMacroglobulinemia (WM).Traditional treatment includes benzenebutanoic acid nitrogen The cell toxicity medicaments such as mustard, endoxan, fludarabine and bendamustine.Though these conventional medicaments can relief of symptoms, not The survival of patients time can effectively be extended.And some patients are poor to chemotherapy side effect, it is bad that patients with recurrent there is also chemotherapeutics Significant reaction increases and antitumor curative effect is reduced etc..
Molecular targeted therapy new drug is according to Shandong for Buddhist nun's (ibrutinib) (formula 1) for Bruton EGFR-TKs (BTK) suppress Agent, its cancer cell that is accurately located at fast-growth different from cellulotoxic chemotherapeutics can avoid the injury to normal cell, Reduce the toxic and side effects such as alopecia, gastrointestinal reaction and the bone marrow suppression of classic chemotherapy medicine.Controlled as MCL and CLL for Buddhist nun according to Shandong Treat medicine and first obtain FDA (Food and Drug Adminstration) (FDA) approval after in November, 2013 and 2 months 2014.The FDA of in January, 2015 The application for expanding idicatio for Buddhist nun according to Shandong is have approved again, i.e., for treating WM.
There are various crystal formations for Buddhist nun's compound according to Shandong.Patent application CN104736178A discloses anhydrous for 3 kinds of Buddhist nun according to Shandong Compound crystal formation (respectively crystal formation A, crystal formation B, crystal formation C) and 3 kinds of solvate crystal formations (respectively MIBK solvates crystal formation D, first Solvate crystal formation E, Methanol solvate crystal formation F), wherein, use recrystallisation solvent methyl tertiary butyl ether(MTBE) (MTBE), diisopropyl Ether (DIPE), ethyl acetate, isopropyl acetate, isopropanol, methyl iso-butyl ketone (MIBK) (MIBK), methyl ethyl ketone (MEK), acetone, Methyl alcohol, nitromethane, 10% water propanone or 10% aqueous isopropanol replace Buddhist nun A to amorphous can acquisition for Buddhist nun's crystallization according to Shandong according to Shandong Crystal formation.According to Shandong for Buddhist nun's A crystal formations X-ray powder diffraction (XRPD) figure 2- θ values be 5.7 ± 0.1 °, 13.6 ± 0.1 °, 16.1 ± There is characteristic peak at 0.1 °, 18.9 ± 0.1 °, 21.3 ± 0.1 ° and 21.6 ± 0.1 °.
Found by the research to various recrystallisation solvents, methyl alcohol, water mixed solvent have more excellent Impurity removal effect, energy Obtain high-purity replaces Buddhist nun's A crystal formations according to Shandong, and crystallized product HPLC purity is more than 99%.And methanol prices are cheap, it is suitable for work Industry metaplasia is produced.But, obtain not good for Buddhist nun's sample appearance according to Shandong is crystallized with methyl alcohol, water mixed solvent, easily form larger hard Block, moisture is difficult removal, and the undue drying temperature or extension time of improving can influence to replace the stability of Buddhist nun according to Shandong;And these are larger Solubility property is poor after lump drying.
CN104327085A discloses a kind of height of the mixed crystallization solvent preparation of use isopropanol or acetone and normal heptane Solubility replaces Buddhist nun's crystal formation according to Shandong, and compared with the crystal formation A of patent WO2013184572A1, the crystal formation solubility of CN104327085 exists 0.15mg/L is brought up to from 0.1mg/L in the simulated intestinal fluid of pH5.0, is brought up to from 0.36mg/L in the simulated gastric fluid of pH1.8 0.5mg/L.The new crystal form X ray powder diffraction pattern of CN104327085A 2- θ values be 5.2 ° ± 0.2 °, 17.6 ° ± 0.2 °, 22.1 ° ± 0.2 °, 19.3 ° ± 0.2 °, 22.4 ° ± 0.2 °, there is at 20.8 ° ± 0.2 ° characteristic peak, and CN104736178A A Crystal formation characteristic peak is entirely different, and actually two kinds different to replace Buddhist nun's crystal formation according to Shandong.
The content of the invention
Found by numerous studies, crystallized with methyl alcohol, water mixed solvent for Buddhist nun according to Shandong and only produce a kind of crystal formation, and use third Ketone, normal heptane mixed solvent crystallization can produce two kinds of different crystal forms.Inventor surprisingly, it is found that, optimization acetone, normal heptane The crystallization processes parameter of mixed solvent, particularly described acetone, normal heptane mixed solvent and Yi Lu for Buddhist nun ratio for 5ml/g~ 50ml/g, can obtain with CN104736178A have same characteristic features peak according to Shandong replace Buddhist nun's A crystal formations.Although A crystal formations of the present invention and The crystal formation of CN104327085A is two kinds of different crystal formations, but A crystal formations outward appearance of the invention is good, and particle is uniform, soluble, molten Solution property is significantly higher than the crystallized product of methyl alcohol, water mixed solvent.Also, acetone, normal heptane mixed solvent be not aqueous, crystallization is easily dried It is dry.
The present invention provide it is a kind of be adapted to it is medicinal according to Shandong for Buddhist nun preparation method, its preparation method comprises the following steps:
(1) first crystallized with methyl alcohol, water mixed solvent;
(2) acetone, normal heptane mixed solvent crystallization, the acetone, normal heptane mixed solvent and Yi Lu is used to replace the ratio of Buddhist nun again Example is 5ml/g~50ml/g;
(3) removal recrystallisation solvent is dried, is obtained and is adapted to medicinal replace Buddhist nun according to Shandong.
Methyl alcohol, water volume ratio are preferably 1 described in the step (1):1~10:1, more preferably 1:1~4:1;
Methyl alcohol, water mixed solvent and Yi Lu described in the step (1) are preferably 1ml/g~100ml/g for the ratio of Buddhist nun, More preferably 5ml/g~50ml/g;
Acetone, normal heptane volume ratio are preferably 1 described in the step (2):1~1:10, more preferably 1:1~1:4;
The drying mode is preferably constant pressure and dry or drying under reduced pressure, is more preferably vacuum dried.
The vacuum drying temperature is preferably 10 DEG C~70 DEG C, more preferably 20 DEG C~60 DEG C, more preferably 25 DEG C~50 DEG C.
Enter on the one hand, the present invention provide it is a kind of be adapted to it is medicinal according to Shandong for Buddhist nun preparation method, its preparation method include it is as follows Step:
(1) take according to Shandong for Buddhist nun's crude product, it is 1 to add volume ratio:1~4:1 methyl alcohol, water mixed solvent, filter after being sufficiently stirred for Obtain solid, vacuum drying;
(2) to learn from else's experience and add volume ratio 1 for Buddhist nun according to Shandong after drying:1~1:4 acetone, normal heptane mixed solvent, are sufficiently stirred for After be filtrated to get solid, the acetone, normal heptane mixed solvent and Yi Lu are 5ml/g~50ml/g for the ratio of Buddhist nun;
(3) vacuum drying removal recrystallisation solvent, obtains and is adapted to medicinal replace Buddhist nun according to Shandong.
Enter on the one hand, preparation method of the present invention according to Shandong for Buddhist nun comprises the following steps:
(1) take according to Shandong for Buddhist nun's crude product, it is 1 to add volume ratio:1~4:1 methyl alcohol, water mixed solvent, filter after being sufficiently stirred for Obtain solid, 25 DEG C~50 DEG C vacuum dryings;
(2) to learn from else's experience and add volume ratio 1 for Buddhist nun according to Shandong after drying:1~1:4 acetone, normal heptane mixed solvent, are sufficiently stirred for After be filtrated to get solid, the acetone, normal heptane mixed solvent and Yi Lu are 5ml/g~50ml/g for the ratio of Buddhist nun;
(3) 25 DEG C~50 DEG C vacuum drying removal recrystallisation solvents, obtain and are adapted to medicinal replace Buddhist nun according to Shandong.
Activated carbon decolorizing can be added in crystallization process, but it is inessential;Can also add crystal seed in crystallization process, but it is non-must Will.
The present invention provide it is a kind of be adapted to it is medicinal according to Shandong for Buddhist nun preparation method, by increasing acetone and normal heptane mixed solvent Crystallisation step, improves the deficiency of methyl alcohol, water mixed solvent crystallized product in terms of moisture and solubility, obtains with high-purity With high-dissolvability Buddhist nun is replaced according to Shandong.The order of the two-step crystallization step is extremely important, and the present invention can not be obtained after putting the cart before the horse It is adapted to medicinal replace Buddhist nun according to Shandong.
The present invention can be also removed effectively according to Shandong for the impurity in Buddhist nun.In single step acetone of the invention, normal heptane mixed solvent Under 4 Crystallization, the A crystal formation HPLC purity for obtaining only has 95%.Using methyl alcohol, water mixed solvent can effectively remove according to Moisture removal is effectively removed in Shandong then for water soluble salt and organic impurities in Buddhist nun's crude product using acetone and normal heptane mixed solvent, Finally vacuum drying removal residual recrystallisation solvent.What the present invention was obtained can reach more than 99.5% according to Shandong for Buddhist nun's purity, and single miscellaneous Less than 0.1%.
It is adapted to medicinal replace Buddhist nun according to Shandong the invention provides a kind of.With A crystal formations disclosed in prior art according to Shandong for Buddhist nun compared with, It is of the invention low for Buddhist nun's impurity content according to Shandong, thus medicine stability is good, it is safe;And high-purity of the invention replaces Buddhist nun according to Shandong Solubility is high, is conducive to improving drug effect, reduces drugloading rate.High-purity of the invention replaces Buddhist nun's preparation process is simple, low cost according to Shandong Honest and clean, optimization and exploitation to medicine have important value.The preparation method is simple, effective, is adapted to large-scale industrial production, With larger commercial application value.
On the other hand, Buddhist nun's preparation is replaced according to Shandong the invention provides one kind, the preparation is by the described high-purity of therapeutically effective amount Du Yilu is mixed for Buddhist nun with one or more pharmaceutic adjuvant.
Brief description of the drawings
Fig. 1 schemes for the XRPD of inventive samples
Specific embodiment
The specific embodiment of form, makees further specifically to the above of the invention by the following examples It is bright.But this scope for being interpreted as above-mentioned theme of the invention should not be only limitted to following examples.
Embodiment 1
According to Shandong for Buddhist nun as prepared by the method described in Chinese patent application CN101610676B.By 101g 4- amino -3- (4- Phenoxyphenyls) -1H- pyrazolos [3,4-d] pyrimidine and 330g polymer connect triphenyl phasphine (TPP) (polymerlab) with 5L tetrahydrofurans (THF) are mixed.To sequentially adding 3- hydroxy piperidine -1- t-butyl formates (200g in gained mixture; 2.0 equivalents), diisopropyl azodiformate (99mL).The reactant mixture is stirred at room temperature overnight.The reaction is filtered to mix Compound, then with purified by flash chromatography (pentane/ethyl acetate=1/1), is obtained with removing resin, and concentrated reaction mixture Intermediate (55g).Above-mentioned intermediate (48.3g) is processed 1 hour with the 4N HCl/ dioxane solutions of 1L, is then concentrated to dryness. Residue is dissolved in dichloromethane, adds triethylamine (42mL), is subsequently added into acryloyl chloride (10mL).Terminate this after 2 hours anti- Should.The reactant mixture is washed with 5% (weight) aqueous citric acid solution, then uses salt water washing.Organic layer is dried simultaneously through MgSO4 Concentration, obtains according to Shandong for Buddhist nun's crude product, and HPLC purity is 90%.
Embodiment 2
Take and replace Buddhist nun crude product 20g according to Shandong according to prepared by embodiment 1,200ml methyl alcohol is dissolved under stirring, under being stirred after dissolving 100ml water is added dropwise over, 3h is kept stirring for after adding, be filtrated to get solid, 45 DEG C of vacuum dryings.What is dried replaces Buddhist nun's solid according to Shandong Containing larger agglomerate thing, dissolubility is bad.
Embodiment 3
Take and add 100ml acetone and 100ml normal heptanes for Buddhist nun's crude product 10g according to Shandong according to prepared by embodiment 1, stir at room temperature 4h is mixed, solid is filtrated to get, 50 DEG C of vacuum drying 4h, obtain A crystal formations replaces Buddhist nun according to Shandong, described small and equal for Buddhist nun's particle according to Shandong Even, dissolubility is good.
Embodiment 4
Take and replace Buddhist nun crude product 20g according to Shandong according to prepared by embodiment 1,200ml methyl alcohol is dissolved under stirring, under being stirred after dissolving 100ml water is added dropwise over, 3h is kept stirring for after adding, be filtrated to get solid, 45 DEG C of vacuum dryings.
Learn from else's experience and add 50ml acetone and 100ml normal heptanes for Buddhist nun 10g according to Shandong after drying, 4h is stirred at room temperature, filter To solid, 30 DEG C of vacuum drying 4h, the high-purity for obtaining A crystal formations replaces Buddhist nun according to Shandong, and HPLC purity is 99.6%, and all impurity are equal Less than 0.1%.
Embodiment 5
Take and replace Buddhist nun crude product 15g according to Shandong according to prepared by embodiment 1,400ml methyl alcohol is dissolved under stirring, under being stirred after dissolving 100ml water is added dropwise over, 4h is kept stirring for after adding, be filtrated to get solid, 30 DEG C of vacuum dryings.
Learn from else's experience and add 25ml acetone and 25ml normal heptanes for Buddhist nun 10g according to Shandong after drying, 3h is stirred at room temperature, be filtrated to get Solid, room temperature in vacuo dries 6h, and obtain A crystal formations replaces Buddhist nun according to Shandong, and sample HPLC purity is 99.7%, and all impurity are below 0.1%.
Embodiment 6
Take and replace Buddhist nun crude product 30g according to Shandong according to prepared by embodiment 1,100ml methyl alcohol is dissolved under stirring, under being stirred after dissolving 100ml water is added dropwise over, 3h is kept stirring for after adding, be filtrated to get solid, 50 DEG C of vacuum dryings.
Learn from else's experience and add 50ml acetone and 200ml normal heptanes for Buddhist nun 5g according to Shandong after drying, 4h is stirred at room temperature, be filtrated to get Solid, 50 DEG C of vacuum drying 8h, obtain A crystal formations replaces Buddhist nun according to Shandong, and sample HPLC purity is 99.7%, and all impurity are below 0.1%.
Embodiment 7
Carry out X-ray powder diffraction for Buddhist nun's sample according to Shandong by what embodiment 2~6 was obtained, collection of illustrative plates 2- θ values be 5.7 ± There is characteristic peak at 0.1 °, 13.6 ± 0.1 °, 16.1 ± 0.1 °, 18.9 ± 0.1 °, 21.3 ± 0.1 ° and 21.6 ± 0.1 °, and specially The crystal formation A of profit application CN104736178A is consistent.The sample collection of illustrative plates of embodiment 3 refers to accompanying drawing 1.

Claims (10)

1. it is a kind of be adapted to it is medicinal according to Shandong for Buddhist nun preparation method, it is characterised in that:
(1) first crystallized with methyl alcohol, water mixed solvent;
(2) use acetone, normal heptane mixed solvent crystallization, the acetone, normal heptane mixed solvent and Yi Lu again is for the ratio of Buddhist nun 5ml/g~50ml/g;
(3) removal recrystallisation solvent is dried, is obtained and is adapted to medicinal replace Buddhist nun according to Shandong.
2. method according to claim 1, it is characterised in that:Methyl alcohol, water volume ratio described in the step (1) are 1:1 ~10:1.
3. method according to claim 1, it is characterised in that:Methyl alcohol described in the step (1), water mixed solvent and according to Shandong is 1ml/g~100ml/g for the ratio of Buddhist nun.
4. method according to claim 1, it is characterised in that:Acetone, normal heptane volume ratio are 1 in the step (2):1 ~1:10.
5. method according to claim 1, it is characterised in that:The drying mode is vacuum drying.
6. method according to claim 1, it is characterised in that:The vacuum drying temperature is 10 DEG C~70 DEG C.
7. method according to claim 1, it is characterised in that:
(1) take according to Shandong for Buddhist nun's crude product, it is 1 to add volume ratio:1~4:1 methyl alcohol, water mixed solvent, are filtrated to get after being sufficiently stirred for Solid, vacuum drying;
(2) to learn from else's experience and add volume ratio 1 for Buddhist nun according to Shandong after drying:1~1:4 acetone, normal heptane mixed solvent, mistake after being sufficiently stirred for Filter obtains solid, and the acetone, normal heptane mixed solvent and Yi Lu are 5ml/g~50ml/g for the ratio of Buddhist nun;
(3) vacuum drying removal recrystallisation solvent, obtains and is adapted to medicinal replace Buddhist nun according to Shandong.
8. method according to claim 1, it is characterised in that:
(1) take according to Shandong for Buddhist nun's crude product, it is 1 to add volume ratio:1~4:1 methyl alcohol, water mixed solvent, are filtrated to get after being sufficiently stirred for Solid, 25 DEG C~50 DEG C vacuum dryings;
(2) to learn from else's experience and add volume ratio 1 for Buddhist nun according to Shandong after drying:1~1:4 acetone, normal heptane mixed solvent, mistake after being sufficiently stirred for Filter obtains solid, and the acetone, normal heptane mixed solvent and Yi Lu are 5ml/g~50ml/g for the ratio of Buddhist nun;
(3) 25 DEG C~50 DEG C vacuum drying removal recrystallisation solvents, obtain and are adapted to medicinal replace Buddhist nun according to Shandong.
9. it is a kind of be adapted to it is medicinal replace Buddhist nun according to Shandong, it is prepared by any one of the claim 1~8 method.
10. one kind replaces Buddhist nun's preparation according to Shandong, medicinal with one or more for Buddhist nun according to Shandong described in the claim 9 by therapeutically effective amount Auxiliary material is mixed.
CN201510980745.3A 2015-12-23 2015-12-23 It is a kind of to be adapted to medicinal replace Buddhist nun and its preparation according to Shandong Pending CN106905320A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510980745.3A CN106905320A (en) 2015-12-23 2015-12-23 It is a kind of to be adapted to medicinal replace Buddhist nun and its preparation according to Shandong

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510980745.3A CN106905320A (en) 2015-12-23 2015-12-23 It is a kind of to be adapted to medicinal replace Buddhist nun and its preparation according to Shandong

Publications (1)

Publication Number Publication Date
CN106905320A true CN106905320A (en) 2017-06-30

Family

ID=59200070

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510980745.3A Pending CN106905320A (en) 2015-12-23 2015-12-23 It is a kind of to be adapted to medicinal replace Buddhist nun and its preparation according to Shandong

Country Status (1)

Country Link
CN (1) CN106905320A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108707154A (en) * 2018-07-10 2018-10-26 刘凤娟 A kind of drug solvent for the treatment of cancer closes object and preparation method thereof
CN115124536A (en) * 2022-07-02 2022-09-30 浙江美诺华药物化学有限公司 Synthesis method of ibrutinib intermediate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103694241A (en) * 2013-11-27 2014-04-02 苏州晶云药物科技有限公司 Novel crystal form A of PCI-32765 and preparation method thereof
CN104736178A (en) * 2012-06-04 2015-06-24 药品循环公司 Crystalline forms of a Bruton's tyrosine kinase inhibitor
WO2015145415A2 (en) * 2014-03-27 2015-10-01 Perrigo Api Ltd. Ibrutinib solid forms and production process therefor
CN105085529A (en) * 2014-05-15 2015-11-25 广东东阳光药业有限公司 Novel crystal form of ibrutinib and preparation method thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736178A (en) * 2012-06-04 2015-06-24 药品循环公司 Crystalline forms of a Bruton's tyrosine kinase inhibitor
CN103694241A (en) * 2013-11-27 2014-04-02 苏州晶云药物科技有限公司 Novel crystal form A of PCI-32765 and preparation method thereof
CN104327085A (en) * 2013-11-27 2015-02-04 苏州晶云药物科技有限公司 PCI-32765 crystal form A and preparation method thereof
WO2015145415A2 (en) * 2014-03-27 2015-10-01 Perrigo Api Ltd. Ibrutinib solid forms and production process therefor
CN105085529A (en) * 2014-05-15 2015-11-25 广东东阳光药业有限公司 Novel crystal form of ibrutinib and preparation method thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
刘新泳: "《实验室有机化合物制备与分离纯化技术》", 31 January 2011, 人民卫生出版社 *
吕扬等: "《晶型药物 2009年10月第1版》", 31 October 2009 *
张磊等: "小分子蛋白酪氨酸激酶抑制剂的研究进展", 《化学试剂》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108707154A (en) * 2018-07-10 2018-10-26 刘凤娟 A kind of drug solvent for the treatment of cancer closes object and preparation method thereof
CN115124536A (en) * 2022-07-02 2022-09-30 浙江美诺华药物化学有限公司 Synthesis method of ibrutinib intermediate

Similar Documents

Publication Publication Date Title
JP2022003052A (en) Rifaximin
CN107108443A (en) The improved method for synthesizing ferric organic compounds
CN112538101A (en) Novel crystal form of beta nicotinamide mononucleotide, preparation method and application thereof
CN111233958B (en) Momordica grosvenori flavin metal zinc complex and preparation method thereof
CN104860939A (en) Cinchona alkaloids compound and preparation method thereof
CN102382034B (en) Synthetic method of N-amino-3-azabicyclo[3,3,0]octane hydrochloride
CN106905320A (en) It is a kind of to be adapted to medicinal replace Buddhist nun and its preparation according to Shandong
CN104788438A (en) B crystal form of empagliflozin and preparation of B crystal form
CN102850411A (en) Preparation method of D-glucosamine sulfate potassium chloride salt
CN107216409A (en) A kind of preparation method of chitosan L malic acid rare earth compoundings
CN102174053B (en) Method for purifying everolimus
CN106518962B (en) Method for preparing reduced glutathione from yeast cells
CN106967064A (en) Deuterated Palbociclib derivative, preparation method and applications
CN108295882B (en) Preparation of core-shell nano catalyst and application of core-shell nano catalyst in preparation of tinib drugs
CN108794473B (en) Perylene bisimide-nojiri toxin derivative and preparation method and application thereof
CN103275168B (en) A kind of preparation method of budesonide
CN109734766A (en) A kind of preparation method of Inflamase intermediate
CN102746227B (en) Dimemorfan phosphate crystal form II and preparation method thereof, and pharmaceutical composition
CN109053808B (en) Industrial preparation method of high-purity dicycloplatin needle crystal
CN104844604B (en) A kind of preparation method of allopurinol sodium
CN113045554A (en) Fexotinib crystal form and preparation method thereof
CN112608317A (en) Sildenafil citrate preparation method
CN110698532A (en) Method for extracting sea cucumber saponin Cladoloside A
CN115260210B (en) Cepharanthine crystal form and preparation method thereof
CN113511967B (en) Method for extracting quinic acid from ginkgo leaf extract chromatographic wastewater

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170630

RJ01 Rejection of invention patent application after publication